Skip to main content
Premium Trial:

Request an Annual Quote

Shares of Sequencing Instrument Makers Fall as Oxford Nanopore Unveils Platforms

NEW YORK (GenomeWeb News) – Shares of players in the sequencing space fell in afternoon trade after Oxford Nanopore unveiled its new nanopore sequencing platform at the Advances in Genome Biology and Technology meeting in Marco Island, Fla.

The Oxford, UK-based firm said that it will begin selling two DNA strand sequencing instruments this year: a higher-throughput version that uses its GridIon platform and a disposable MinIon system that will be the size of a USB memory stick and cost less than $900. At launch, both systems are expected to deliver read lengths of up to 100 kilobases with raw read error rates of about 1 percent.

(For more on the expected performance and costs associated with the instruments, see GenomeWeb Daily News sister publication In Sequence).

The company is not yet taking orders for the platforms but plans to launch the systems commercially during the second half of this year.

"If performance is as highlighted, Oxford Nanopore's technology could be a game changer for not only the research lab but also for applied settings such as clinical diagnostics," Mizuho Securities analyst Peter Lawson said in a note published this afternoon.

News of the new competitor sent other established players on a downward trend today.

In mid-afternoon trade on the Nasdaq, shares of Life Technologies were down 6 percent at $47.01, Illumina fell 3 percent to $52.35, Pacific Biosciences dropped 5 percent to $4.79, and Complete Genomics slipped 3 percent to $3.86.

"We think that the markets are overreacting to the news today of a competing sequencing technology," Robert W. Baird analyst Quintin Lai said in a note. "While Oxford's announcement shows promise, we believe the court of scientific opinion and early access users will be the real determinant if the platform is commercially successful."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more